Duke William E. sold $32K of IVVD

Duke William E. (Chief Financial Officer) sold 40,780 shares of Invivyd, Inc. (IVVD) at an average of $0.78 ($0.72–$0.84) across 2 trades over 2026-08-17 to 2026-08-18 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Duke William E.
Published Aug 19, 2026, 12:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 19, 2026, 12:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IVVD
Neutral
medium confidence
Mentioned
$IVVD
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IVVDNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price range, and confirmation of a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but this filing alone does not provide new operational or financial guidance.

03

What to watch

Insider sales can be driven by diversification, taxes, or scheduled liquidity needs; without accompanying guidance, trial, financing, or operational updates, the signal is weak.

Relevance 2/10Novelty 3/10Timing: filed Aug. 18 after trades on Aug. 17-18

Background

This is an SEC Form 4 insider transaction disclosure for Invivyd, Inc., reported by the CFO.

Company-level read

Ticker impact

$IVVDNeutralMedium confidence
Context

Invivyd CFO Duke William E. sold 40,780 shares in open-market transactions at $0.7220 to $0.8429, per Form 4 filed Aug. 18.

Expected impact

Limited, likely sentiment-only impact; any move would be small unless accompanied by other company-specific catalysts.

Evidence & confidence

Form 4 shows a planned sale (10b5-1) with modest dollar value (~$31.7k) relative to typical market caps, so the information is more about positioning than new business fundamentals.

Market effects

No clear sector read-through from a single planned insider sale.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may be routine and not signal reduced confidence; traders may overreact to the headline.

Key entities

  • Invivyd, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Duke William E.

    Chief Financial Officer who executed the sale(s).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IVVDMed

Invivyd Posts Wider Loss In Q3 As Operating Expenses Rise

Invivyd, Inc. (IVVD) reported a wider Q3 net loss of $33.47 million, up from $10.47 million YoY, due to higher operating expenses. Revenue rose 18% to $15.45 million. The company provided updates on its pipeline, including VYD2311 for COVID-19 and VMS063 for measles, and announced leadership changes. Cash reserves totaled $126.40 million.

$IVVDHigh

Invivyd Reports Third Quarter 2026 Financial Results and Recent

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights • DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently, per the Accelerated Approval analysis and regulatory submission plan previously communic

$IVVDMedAI 8/10

Invivyd presents preclinical data on measles antibody candidate

Invivyd (NASDAQ:IVVD) presented preclinical data for its measles antibody candidate VMS063 at IDWeek 2026, showing antiviral activity against measles virus variants. The company plans to scale up manufacturing for clinical development in 2027. There are currently no FDA-approved treatments for measles, with U.S. cases nearly double in 2026 compared to 2025, according to Invivyd.

$IVVDLow

Invivyd, Inc. (IVVD) Unveils Preclinical Data for Measles mAb VMS063

Invivyd, Inc. (IVVD) presented preclinical data for VMS063, a novel monoclonal antibody for measles, showing in vitro activity against contemporary virus variants. The company is scaling up production for clinical development in 2027. There are currently no FDA-approved treatments for measles, and the U.S. is experiencing a surge in cases.

$IVVDLowAI 8/10

More than 9 million U.S. children are estimated to lack measles protection. Lab tests found an antibody could fight measles.

Invivyd (Nasdaq: IVVD) presented preclinical data for VMS063, a monoclonal antibody candidate for measles treatment and prevention. VMS063 showed potent in vitro activity against measles virus variants. Invivyd plans to scale up production for clinical development in 2027. The U.S. is experiencing a record number of measles cases in 2026, with over 9 million children unprotected.